vs

Side-by-side financial comparison of Idaho Strategic Resources, Inc. (IDR) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Idaho Strategic Resources, Inc. is the larger business by last-quarter revenue ($14.6M vs $12.5M, roughly 1.2× Avidity Biosciences, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -1398.3%, a 1462.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 92.0%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 57.2%).

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

IDR vs RNA — Head-to-Head

Bigger by revenue
IDR
IDR
1.2× larger
IDR
$14.6M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+342.0% gap
RNA
434.0%
92.0%
IDR
Higher net margin
IDR
IDR
1462.6% more per $
IDR
64.3%
-1398.3%
RNA
More free cash flow
IDR
IDR
$165.0M more FCF
IDR
$8.2M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
57.2%
IDR

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IDR
IDR
RNA
RNA
Revenue
$14.6M
$12.5M
Net Profit
$9.4M
$-174.4M
Gross Margin
68.5%
Operating Margin
62.4%
-1513.5%
Net Margin
64.3%
-1398.3%
Revenue YoY
92.0%
434.0%
Net Profit YoY
220.6%
-117.0%
EPS (diluted)
$0.62
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDR
IDR
RNA
RNA
Q4 25
$14.6M
Q3 25
$11.1M
$12.5M
Q2 25
$9.5M
$3.8M
Q1 25
$7.3M
$1.6M
Q4 24
$7.6M
$3.0M
Q3 24
$6.2M
$2.3M
Q2 24
$6.1M
$2.0M
Q1 24
$5.9M
$3.5M
Net Profit
IDR
IDR
RNA
RNA
Q4 25
$9.4M
Q3 25
$3.0M
$-174.4M
Q2 25
$2.8M
$-157.3M
Q1 25
$1.6M
$-115.8M
Q4 24
$2.9M
$-102.3M
Q3 24
$1.6M
$-80.4M
Q2 24
$2.2M
$-70.8M
Q1 24
$2.2M
$-68.9M
Gross Margin
IDR
IDR
RNA
RNA
Q4 25
68.5%
Q3 25
63.6%
Q2 25
57.8%
Q1 25
50.8%
Q4 24
53.3%
Q3 24
48.7%
Q2 24
50.2%
Q1 24
48.1%
Operating Margin
IDR
IDR
RNA
RNA
Q4 25
62.4%
Q3 25
23.4%
-1513.5%
Q2 25
26.6%
-4448.7%
Q1 25
19.3%
-8360.9%
Q4 24
36.2%
-4069.6%
Q3 24
23.4%
-4200.9%
Q2 24
34.2%
-4040.4%
Q1 24
36.3%
-2178.6%
Net Margin
IDR
IDR
RNA
RNA
Q4 25
64.3%
Q3 25
26.8%
-1398.3%
Q2 25
29.2%
-4089.3%
Q1 25
22.1%
-7360.0%
Q4 24
38.5%
-3439.5%
Q3 24
25.8%
-3441.7%
Q2 24
35.2%
-3461.8%
Q1 24
36.8%
-1943.4%
EPS (diluted)
IDR
IDR
RNA
RNA
Q4 25
$0.62
Q3 25
$0.20
$-1.27
Q2 25
$0.20
$-1.21
Q1 25
$0.12
$-0.90
Q4 24
$0.21
$-0.80
Q3 24
$0.12
$-0.65
Q2 24
$0.17
$-0.65
Q1 24
$0.17
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDR
IDR
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$108.2M
$1.9B
Total Assets
$116.2M
$2.1B
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDR
IDR
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$6.3M
$575.8M
Q1 24
$5.3M
$471.4M
Total Debt
IDR
IDR
RNA
RNA
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
Q2 24
$2.7M
Q1 24
$3.3M
Stockholders' Equity
IDR
IDR
RNA
RNA
Q4 25
$108.2M
Q3 25
$74.3M
$1.9B
Q2 25
$49.3M
$1.2B
Q1 25
$39.8M
$1.3B
Q4 24
$37.7M
$1.4B
Q3 24
$33.1M
$1.5B
Q2 24
$25.4M
$1.2B
Q1 24
$21.6M
$830.9M
Total Assets
IDR
IDR
RNA
RNA
Q4 25
$116.2M
Q3 25
$83.1M
$2.1B
Q2 25
$57.7M
$1.4B
Q1 25
$48.1M
$1.5B
Q4 24
$44.0M
$1.6B
Q3 24
$40.8M
$1.6B
Q2 24
$32.2M
$1.3B
Q1 24
$28.7M
$951.5M
Debt / Equity
IDR
IDR
RNA
RNA
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
Q2 24
0.11×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDR
IDR
RNA
RNA
Operating Cash FlowLast quarter
$10.7M
$-156.2M
Free Cash FlowOCF − Capex
$8.2M
$-156.9M
FCF MarginFCF / Revenue
56.0%
-1257.6%
Capex IntensityCapex / Revenue
17.7%
5.7%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDR
IDR
RNA
RNA
Q4 25
$10.7M
Q3 25
$2.4M
$-156.2M
Q2 25
$3.5M
$-199.7M
Q1 25
$2.4M
$-124.8M
Q4 24
$3.2M
$-99.9M
Q3 24
$2.5M
$-65.6M
Q2 24
$2.6M
$-65.0M
Q1 24
$2.6M
$-70.4M
Free Cash Flow
IDR
IDR
RNA
RNA
Q4 25
$8.2M
Q3 25
$709.8K
$-156.9M
Q2 25
$2.5M
$-203.0M
Q1 25
$1.0M
$-128.6M
Q4 24
$2.1M
$-103.8M
Q3 24
$1.9M
$-67.3M
Q2 24
$2.4M
$-65.5M
Q1 24
$2.3M
$-71.3M
FCF Margin
IDR
IDR
RNA
RNA
Q4 25
56.0%
Q3 25
6.4%
-1257.6%
Q2 25
26.5%
-5277.1%
Q1 25
13.8%
-8174.3%
Q4 24
28.0%
-3491.0%
Q3 24
30.4%
-2881.8%
Q2 24
38.7%
-3204.6%
Q1 24
38.3%
-2012.3%
Capex Intensity
IDR
IDR
RNA
RNA
Q4 25
17.7%
Q3 25
15.3%
5.7%
Q2 25
10.8%
86.9%
Q1 25
19.4%
238.6%
Q4 24
13.6%
131.7%
Q3 24
9.8%
72.9%
Q2 24
4.3%
26.0%
Q1 24
5.5%
25.8%
Cash Conversion
IDR
IDR
RNA
RNA
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons